Navigating Barriers in Adult GHD Management

This episode focuses on the real-world access challenges that clinicians and patients with adult GHD face — including insurance denials, documentation requirements, and strategies for obtaining and sustaining GH therapy approvals.

Dr. Agrawal opens with a frank observation: insurance companies frequently do not understand adult GHD. The term “growth hormone” creates conceptual confusion for payers who associate GH exclusively with childhood height. She suggests that adult GHD might benefit from reframing — as a metabolic disease, for example — to help payers understand its systemic and long-term health implications. Until then, comprehensive documentation aligned with FDA indications and clinical guidelines remains the clinician’s primary tool.

Practical documentation strategies discussed by the panel include: citing FDA-approved indications explicitly in clinical notes, including all pediatric GH history and testing when available, compiling a complete prior authorization package that tells a coherent clinical narrative, and in some cases requiring patients to demonstrate failure on daily GH before gaining insurance approval for weekly analogs.

Dr. Garcia underscores that a formal transition clinic would be the ideal solution for documentation continuity — with all records centralized and specialists from both sides co-present. He confirms that most of his transitioning patients arrive with adequate prior testing in place, reducing the need for complete retesting.

The episode closes with a broader discussion on optimizing long-term adult GHD care. Dr. Garcia stresses the value of patient engagement: understanding what matters to each patient — whether fatigue, mood, body composition, or general wellbeing — and framing treatment goals around those priorities dramatically improves adherence. Dr. Yang reinforces that GHD is not simply a growth condition that ends in adulthood; some of the most serious metabolic and skeletal consequences can emerge or worsen in adult years.

In the next episode, “Growth Hormone Deficiency in Cancer Survivors,” the panel tackles GH use in patients with active or prior malignancy.